<article id="weyckler_2006_p" class="slide" data-ag-slide-name="Weyckler 2006 (P)">
    <div class="basic">
       <h1 class="larger_title" data-ag-editable="Weycker 2006 (P) Main Title">“Evidence from multiple low level studies derived from audit data and clinical practice suggests that some patients receive suboptimal daily G-CSFs; the use of pegfilgrastim may avoid this problem.”<sup>[EORTC guidelines 2010]1</sup></h1>
       <div id="fn_page2_top_p">
          <p class="red_subtitle2" data-ag-editable="Weycker 2006 (P) Top Copy">Risk of hospitalisation vs days of filgrastim prophylaxis<sup>2</sup></p>
       </div>
       <div id="weyckler_2006_p_graph_holder">
          <div id="weyckler_2006_p_large" class="main_content_style">
             <img src="content/images/carer_pages/burden_of_fn/weycker_2006_large.png" width="788" height="564" data-ag-editable="Weycker 2006 P Graph Background" />
             <div id="weyckler_2006_graph_vertical_numbers">
                <ul data-ag-editable="Weycker 2006 (P) Graph Vertical Axis Data">
                   <li>40%</li>
                   <li>35%</li>
                   <li>30%</li>
                   <li>25%</li>
                   <li>20%</li>
                   <li>15%</li>
                   <li>10%</li>
                   <li>5%</li>
                   <li>0%</li>
                </ul>
             </div>
             <div id="weyckler_2006_graph_horizontal_numbers">
                <ul data-ag-editable="Weycker 2006 (P) Graph Horizontal Axis Data">
                   <li>1</li>
                   <li>2</li>
                   <li>3</li>
                   <li>4</li>
                   <li>5</li>
                   <li>6</li>
                   <li>7</li>
                   <li>8</li>
                   <li>9</li>
                   <li>10</li>
                   <li>11</li>
                   <li>12</li>
                   <li>13</li>
                   <li>14</li>
                </ul>
             </div>
             <div id="weyckler_2006_p_graph_content_large">
                 <p id="graph1_vertical_axis_title_large" data-ag-editable="Weyckler 2006 P Vertical Axis Title">Risk of hospitalisation</p>
                 <p id="graph1_horizontal_axis_title_large" data-ag-editable="Weyckler 2006 Horizontal Axis Title">Days of filgrastim prophylaxis</p>
                 <p id="graph1_legend_1_large" data-ag-editable="Weyckler 2006 P Graph Legend 1">Breast Cancer</p>
                 <p id="graph1_legend_2_large" data-ag-editable="Weyckler 2006 P Graph Legend 2">Non-Hodgkin's Lymphoma</p>
                 <p id="graph1_legend_3_large" data-ag-editable="Weyckler 2006 P Graph Legend 3">Lung Cancer</p>
                 <p id="graph1_bottom_text_large" data-ag-editable="Weyckler 2006 P Bottom Text">Adapted from Weyckler D <em>et al.</em> Ann Phamaco 2006; 40(3);402-407</p>
             </div>
          </div>
       </div>
       <div id="fn_page2_bottom_p">
          <ul class="red_dot_list" data-ag-editable="Weycker 2006 (P) Bottom List Copy">
             <li><p>Decreasing the duration of daily filgrastim use from <strong>10 days to 6 days increases the risk of</strong> hospitalisation due to FN in breast cancer patients from <strong>4% to 12%</strong><sup>2</sup></p></li>
             <li><p>Frequent monitoring of ANC per cycle is required for accurate dosing with daily filgrastim<sup>2,3</sup></p></li>
          </ul>
       </div>
    </div>
    <div class="enlarge_graph" id="enlarge_graph_weyckler_2006_p"></div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="weyckler_2006_p_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="Weycker 2006 (P) References Title">References:</strong><br /><br /></p>
          <div data-ag-editable="Weycker 2006 (P) References List">
             <ol>
                <li>Aapro M <em>et al</em>. 2010 update of EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47(1):8-32</li>
                <li>Weycker D <em>et al</em>. Are Shorter Courses of Filgrastim Prophylaxis Associated with Increased Risk of Hospitalisation? Ann Phamaco 2006; 40(3):402-407</li>
                <li>Neupogen<sup>®</sup>, Summary of Product Characteristics, March 2011</li>
             </ol>
          </div>
          <p data-ag-editable="Weycker 2006 (P) References Bottom Copy">The recommended dose of filgrastim (NEUPOGEN<sup>®</sup>) is 0.5 MU (5 μg/kg/day). Daily dosing with NEUPOGEN<sup>®</sup> should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to normal range.<sup>3</sup><br /><br />
       Predicted risk of hospitalisation for neutropenia or infection. Based on coefficients from generalised estimating model and assuming mean Charlson Comorbidity index, cycle and no recent history of hospitalisation or anemia for neutropenia or infection.<sup>2</sup></p>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>